Engage Bio
Engage Bio is developing Tethosomes, a new class of non-viral genetic medicines engineered for potency, safety, and specificity. Tethosomes achieve over 100x higher expression than traditional DNA-based vectors. Further, Tethosomes evade detection by the innate immune system, finally enabling safe and redosable non-viral DNA therapies. The programmability and specificity of Tethosomes enable broad therapeutic applications ranging from gene replacement to cancer immunotherapy.
